Navigation Links
Cambrex Reports First Quarter 2009 Results
Date:5/5/2009

First quarter 2009 Gross Margin decreased to 31.9% of sales from 35.5% during the first quarter 2008, with foreign currency favorably impacting gross margin by 6.0%. Lower production levels and the accompanying lower absorption compared to the prior year's first quarter, along with slightly higher production costs were the main drivers of the lower margins.

Selling, General and Administrative Expenses in the first quarter 2009 were $9.0 million compared to $11.3 million in the same period last year. The decrease is a result of lower corporate headquarters expenses due to restructuring activities, expense reductions within the Company's manufacturing sites and the favorable impact of foreign currency.

Research and Development ("R&D") Expenses for the first quarter 2009 were $1.7 million compared to $2.3 million in the first quarter 2008. The decrease is primarily due to the increased utilization of certain R&D personnel on custom development projects resulting in these costs being classified as either Inventory or Cost of Goods Sold and the consolidation of the New Jersey R&D facility into the Iowa facility.

Operating Profit increased to $8.3 million in the first quarter 2009 from $7.5 million in the first quarter 2008. Operating Profit, excluding 2008 Restructuring Expenses and Strategic Alternative Costs of $811, was flat quarter over quarter. EBITDA was $13.0 million, or 21.7% of sales, compared to adjusted EBITDA of $13.5 million, or 21.9% of sales last year. This decrease is due primarily to lower gross margins in the first quarter of 2009.

Steven M. Klosk, President and Chief Executive Officer, said, "We are pleased with the volume growth in the first quarter and we continue to benefit from our operating cost reduction activities. Our cash flow, excluding certain items, was positive for the quarter and we are taking further actions to improve our management of working capital
'/>"/>

SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cambrex Receives Notice Regarding NYSE Listing
2. Cambrex Reports Third Quarter 2008 Results
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
5. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
6. Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results
7. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
8. United Therapeutics Reports First Quarter 2009 Financial Results
9. Osteotech Reports First Quarter 2009 Financial Results
10. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
11. Idenix Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Draper University, ... is proud to announce that for 6 weeks ... countries will converge on the Draper University campus ... intensive, experiential program focused on entrepreneurship, building real-world ... school, currently running its sixth cohort, continues to ...
(Date:7/23/2014)... YORK , July 24, 2014 ... Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First ... "Immune" or "the Company"), announced a collaboration to ... pemphigoid last night at an event attended by ... interested parties. Lyfebulb is a health and wellness ...
(Date:7/23/2014)... Dresden-Rossendorf (HZDR), the Vienna University of Technology and ... embedding nearly perfect semiconductor crystals into a silicon ... nanowires, very fast and multi-functional processing units can ... future. The research results will be published in ... are considered the cornerstone of future chip technology, ...
(Date:7/23/2014)... DENVER , July 23, 2014  Having the ... making is vital to accelerating business growth and achieving ... American Hospital Association (AHA) Leadership Summit, July 20-22, 2014, ... prestigious panel of hospital executives and healthcare experts discussing ... Joanne Carrocino , President & Chief Executive Officer ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5A crystal wedding in the nanocosmos 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2
... plc,(LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical ... Standards ("IFRS") for the twelve months to December ... announced its results for the same period,under US ... Shire,s strategic goal is to become the ...
... IRVINE, Calif., March 25 Masimo (Nasdaq:,MASI), ... Motion and Low,Perfusion pulse oximetry, today announced ... manufacturer and supplier of,electrocardiographs, spirometers, patient monitors ... SET technology platform as,the foundational technology of ...
... NEOG ) announced today that its net income for ... increased 34% from the previous year,s third,quarter. Net income ... share,compared to the prior year,s $1,990,000 ($0.14 per share). ... 2008 fiscal year increased 31%,to $8,923,000 from $6,822,000 in ...
Cached Biology Technology:Shire plc: IFRS Results for the Year Ending December 31, 2007 2Shire plc: IFRS Results for the Year Ending December 31, 2007 3Shire plc: IFRS Results for the Year Ending December 31, 2007 4Shire plc: IFRS Results for the Year Ending December 31, 2007 5Shire plc: IFRS Results for the Year Ending December 31, 2007 6Shire plc: IFRS Results for the Year Ending December 31, 2007 7Shire plc: IFRS Results for the Year Ending December 31, 2007 8Shire plc: IFRS Results for the Year Ending December 31, 2007 9Shire plc: IFRS Results for the Year Ending December 31, 2007 10Shire plc: IFRS Results for the Year Ending December 31, 2007 11Shire plc: IFRS Results for the Year Ending December 31, 2007 12Shire plc: IFRS Results for the Year Ending December 31, 2007 13Shire plc: IFRS Results for the Year Ending December 31, 2007 14Shire plc: IFRS Results for the Year Ending December 31, 2007 15Shire plc: IFRS Results for the Year Ending December 31, 2007 16Shire plc: IFRS Results for the Year Ending December 31, 2007 17Shire plc: IFRS Results for the Year Ending December 31, 2007 18Shire plc: IFRS Results for the Year Ending December 31, 2007 19Shire plc: IFRS Results for the Year Ending December 31, 2007 20Shire plc: IFRS Results for the Year Ending December 31, 2007 21Shire plc: IFRS Results for the Year Ending December 31, 2007 22Shire plc: IFRS Results for the Year Ending December 31, 2007 23Shire plc: IFRS Results for the Year Ending December 31, 2007 24Shire plc: IFRS Results for the Year Ending December 31, 2007 25Shire plc: IFRS Results for the Year Ending December 31, 2007 26Shire plc: IFRS Results for the Year Ending December 31, 2007 27Shire plc: IFRS Results for the Year Ending December 31, 2007 28Shire plc: IFRS Results for the Year Ending December 31, 2007 29Shire plc: IFRS Results for the Year Ending December 31, 2007 30Shire plc: IFRS Results for the Year Ending December 31, 2007 31Shire plc: IFRS Results for the Year Ending December 31, 2007 32Shire plc: IFRS Results for the Year Ending December 31, 2007 33Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide 2Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide 3Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide 4
(Date:7/24/2014)... . , Electric cars ... common sight on the roads of the Scandinavian country ... new vehicle registrations for the second time. This poses a ... claim only a small portion of the market. Of the ... mere 8000 are electric powered. The main factors discouraging motorists ...
(Date:7/23/2014)... 24, 2014 Pfenex Inc. (NYSE MKT: PFNX) today ... shares of its common stock at a price to the ... the underwriters a 30-day option to purchase up to 1,250,000 ... price. The shares are expected to begin trading on the ... William Blair & Company, L.L.C. and ...
(Date:7/23/2014)... (SMU) The U.S. Department of Defense recently ... a $2.6 million grant to support its goal ... fields. STEMPREP recruits bright, science-minded minority middle school ... STEMPREP project, then provides high school students with ... based at SMU,s Annette Caldwell Simmons School of ...
Breaking Biology News(10 mins):Nano-supercapacitors for electric cars 2Nano-supercapacitors for electric cars 3Pfenex Inc. Announces Pricing Of Initial Public Offering 2Department of Defense awards $2.6 million grant to SMU STEM program for minority students 2
... April 11, 2011 (BRONX, NY) Just as inhaling ... it. Two researchers at Albert Einstein College of Medicine ... grant from the National Institutes of Health to clinically develop ... before the cancer becomes malignant and spreads. The grant ...
... SEATTLE, Wash.April 12, 2011The Allen Institute for Brain ... genomically comprehensive human brain map, a previously unthinkable ... than four years of rigorous studies and documentation. ... Allen Human Brain Atlas, an online public resource ...
... material available to identify persons or find next of kin ... the kits usually employed to carry out DNA identifications do ... is not available, and that which is available is highly ... persons from these small fragments of DNA. His thesis, presented ...
Cached Biology News:NIH funds investigation of inhaled lung cancer treatment 2Allen Institute for Brain Science announces first comprehensive gene map of the human brain 2Allen Institute for Brain Science announces first comprehensive gene map of the human brain 3Developing a tool for identification -- even using very degraded DNA samples 2Developing a tool for identification -- even using very degraded DNA samples 3